ArticleFrontiers in immunology2017
Assessment of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.The Journal of clinical investigation · 2021Trial
- Computational Development of Transmission-Blocking Vaccine Candidates Based on Fused Antigens of Pre- and Post-fertilization Gametocytes AgainstBioinformatics and biology insights · 2025Article
- Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024Review
- Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.EBioMedicine · 2024Article
- Evaluation of transmission-blocking potential of PvPSOP25 using transgenic murine malaria parasite and clinical isolates.PLoS neglected tropical diseases · 2024Article
- Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates inmedRxiv : the preprint server for health sciences · 2024Article
- mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response.NPJ vaccines · 2024Article
- Intranasal trivalent candidate vaccine induces strong mucosal and systemic immune responses againstFrontiers in immunology · 2024Article
- Current approaches to malaria vaccines.Current opinion in microbiology · 2022Review
- Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design.Scientific reports · 2022Article
- The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine Candidate.The American journal of tropical medicine and hygiene · 2022Article
- Characterization of PSOP26 as an ookinete surface antigen with improved transmission-blocking activity when fused with PSOP25.Parasites & vectors · 2022Article
- Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.The Journal of infection · 2022Article
- Article
- Computational Clues of Immunogenic Hotspots inBioMed research international · 2022Article
- Review
- Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination.Expert review of vaccines · 2021Review
- Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs.Frontiers in immunology · 2021Article
- Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas AgainstFrontiers in immunology · 2021Article
- Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.Malaria journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
A malaria transmission-blocking vaccine would be a critical tool in achieving malaria elimination and eradication. By using chimpanzee adenovirus serotype 63 and modified vaccinia virus Ankara viral vectored vaccines, we investigated whether incorporating two antigens into one vaccine would result in higher transmission-reducing activity than one antigen. We demonstrated that when Pfs25 was administered with other antigens Pfs28 or Pfs230C, either concurrently as a mixed vaccine or co-expressed as a dual-antigen vaccine, the antibody response in mice to each antigen was comparable to a monoantigen vaccine, without immunological interference. However, we found that the transmission-reducing activity (functional activity) of dual-antigen vaccines was not additive. Dual-antigen vaccines generally only elicited similar transmission-reducing activity to monoantigen vaccines and in one instance had lower transmission-reducing activity. We found that despite the lack of immunological interference of dual-antigen vaccines, they are still not as effective at blocking malaria transmission as Pfs25-IMX313, the current leading candidate for viral vectored vaccines. Pfs25-IMX313 elicited similar quality antibodies to dual-antigen vaccines, but higher antibody titers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.